Loading…
← CockpitCompetitor Analysis › 476060.KS Onconic Therapeutics, Inc.Open in the cockpit ↗

Onconic Therapeutics, Inc.476060.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Biotechnology
Momentum weak 24
Mkt cap
$368M
US dollars, full cap
Free float
50%
of shares outstanding
$/day
$1.39M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+48.6 pp
WACC 5.7%
Hurdle
-725 pp
Req g minus delivered
Close · KRW₩10,550
1D+0.5%
1W-15.9%
1M-22.4%
3M-28.8%
6M-49.3%
YTD-46.0%
1Y-25.1%
ATR %7.9%
52w lowhigh63.5% off high

What Onconic Therapeutics does

Employees: 38

Onconic Therapeutics at a glance

Size Onconic Therapeutics (476060.KS) is a South Korea Health Care company (Biotechnology) with a market value of $368M, the 426th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩10,550 on 18 Nov 2026.

Performance Over six months the shares fell 49.3%, against -23.6% for the median peer and -37.2% for the South Korea market (cap-weighted) — lowest of 20 in its peer set.

Growth Revenue grew 179.3% over the last twelve months (peer median +6.3%); the operating margin is 21.1% (peer median -2.0%).

Valuation It trades at 5.2× enterprise value to sales against a peer median of 2.6× (6th most expensive of 16).

Price implies For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +725%, so the hurdle is -725 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 48.6 points above its cost of capital (5.7% WACC).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 73476060.KS 54
Six months, rebased to 100: Onconic Therapeutics against the median of its 20 peers (local-currency closes).

Onconic Therapeutics financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩82.2B₩53.4B₩14.8B₩21.1B₩95.0M
Revenue growth—+260%-30%+22,064%—
Gross profit₩37.2B₩25.5B₩8.53B₩19.3Bn/a
EBITDA₩17.9B₩13.1B-₩4.35B₩2.69B-₩14.6B
Net income₩24.3B₩15.8B-₩8.09B₩1.68B-₩14.4B
Free cash flow₩16.5B₩11.1B-₩7.98B₩2.98B-₩17.5B
Capital expenditure₩317M₩303M₩141M₩1.16B₩2.58B
Total debt₩271M₩126M₩308M₩14.1B₩12.1B

Quarterly statements and history in the cockpit →

Onconic Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-25%0%+25%300381CTNMCRMDPRTCALEC300966086900PNV688687300683LYEL358570LRMR68809811673378476060.KS6-month return →1-month return →
Up and to the right = strong over both horizons. Onconic Therapeutics is the large dot.

Fundamentals: revenue growth against valuation

0%+500%+1,000%+1,500%0×5,000×10,000×15,000×300381CRMDLYEL35857011676998476060.KSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Onconic Therapeutics is the large dot.

Capital: growth delivered against growth the price implies

0%+200%+400%+600%0%250%500%750%086900PNV68868711676998476060.KSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Onconic Therapeutics is the large dot.

Onconic Therapeutics competitors and peer comparison

How Onconic Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Onconic Therapeutics against its 20 peers (data as of 18 Nov 2026)
Measure476060.KSPeer medianRank in peer set
1-month return-22.4%-5.4%3rd lowest of 20
6-month return-49.3%-23.6%lowest of 20
Distance from 52-week high-63.5%-47.2%4th lowest of 20
Revenue growth (TTM)+179.3%+6.3%4th highest of 16
Operating margin21.1%-2.0%6th highest of 16
EV / Sales5.2×2.6×6th most expensive of 16
Growth the price implies (Req g, 7 yrs)0.6%4.7%3rd least demanding of 6
Growth delivered (Del g)+725.2%+11.9%highest of 6
Hurdle (Req g minus delivered)-724.6 pp+14.3 ppleast demanding of 6
ROIC minus cost of capital+48.6 pp-9.2 pphighest of 16
EV / EBITDA23.8×5.8×2nd most expensive of 8
Net debt / EBITDA-3.5×-2.3×3rd least indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Onconic Therapeutics 476060.KSSouth Korea$368M-49%+179%21%5.2×0.6%+725.2%
Guangdong Vtr Bio-Tech 300381.SZChina$370M-31%0%-4%2.6×n/an/a
Contineum Therapeutics CTNMUnited States$363M-31%n/an/an/an/an/a
CorMedix CRMDUnited States$358M-43%+92%39%0.4×n/an/a
PureTech Health PRTC.LUnited Kingdom$378M-15%-4%-1,617%27.4×n/an/a
Alector ALECUnited States$383M+21%+151%25%1.5×n/an/a
Hubei Goto Biopharm 300966.SZChina$386M-16%+6%-10%6.0×n/an/a
Medy-Tox 086900.KSSouth Korea$350M-36%+3%10%2.2×4.7%+11.9%
Aspen Neuroscience ASPEUnited States$349Mn/an/an/an/an/an/a
Polynovo PNV.AXAustralia$388M-34%+13%5%3.9×51.9%+37.6%
Beijing Kawin Technology Share-Holding 688687.SSChina$391M-20%+6%-2%1.7×36.6%+8.9%
Wuhan Hiteck Biological Pharma 300683.SZChina$395M-41%-30%-27%5.2×n/an/a
Lyell Immunopharma LYELUnited States$341M-19%-63%-1,388,360%13,911.5×n/an/a
Beijing Luzhu Biotechnology 2480.HKHong Kong$396M-33%n/an/an/an/an/a
GI Innovation 358570.KSSouth Korea$339M-47%+1,527%-918%78.5×n/an/a
Larimar Therapeutics LRMRUnited States$337M-9%n/an/an/an/an/a
Shanghai Shen Lian Biomedical 688098.SSChina$402M-22%-17%-16%10.9×n/an/a
Jacobio Pharmaceuticals 1167.HKHong Kong$404M-24%+286%68%1.9×-18.8%-36.1%
Medtide 3880.HKHong Kong$331M-17%+14%36%2.4×n/an/a
Hanx Biopharmaceuticals (Wuhan) 3378.HKHong Kong$409M-24%n/an/an/an/an/a
Edding Genor 6998.HKHong Kong$410M-35%+1,418%26%1.0×-15.3%+197.3%

Questions

Which companies are Onconic Therapeutics's closest peers?
The cockpit's peer set: Guangdong Vtr Bio-Tech (300381.SZ), Contineum Therapeutics (CTNM), CorMedix (CRMD), PureTech Health (PRTC.L), Alector (ALEC), Hubei Goto Biopharm (300966.SZ), Medy-Tox (086900.KS), Aspen Neuroscience (ASPE).
Is Onconic Therapeutics expensive compared with its peers?
On ev / sales it trades at 5.2× against a peer median of 2.6×, 6th most expensive of 16 in its peer set. For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +725%, so the hurdle is -725 pp: the price already allows for a slowdown.
How has Onconic Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -49.3% against -23.6% for the median peer; over one year -25.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.